Manas Mishra on Muck Rack

Manas Mishra

Verified
Bangalore, India
As seen in: Citeline, MSN, MSN Australia, MSN Canada, MSN Singapore, O Globo, UOL, Yahoo Life, Business Insider, Daily Mail, Estadão and
@Reuters. Follow for healthcare/business related news and my obscure interests on your feed. Opinions are mine, and not those of my employer.

Get in touch with Manas

Contact Manas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

enGene Retrenches On Detalimogene As Bladder Cancer Race Tightens

|
By Manas Mishra 
| Scrip
After a disappointing update on detalimogene voraplasmid in May, EnGene will cut down its workforce by half and let several executives go to focus attention on a H2 2026 FDA filing. (Shutterstock) enGene Therapeutics is cutting its workforce in half and discontinuing several cohorts of a Phase II study to preserve cash ahead of a planned US Food and Drug Administration filing for detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC).
Open in Who Shared Issue with article?
|
By Manas Mishra 
| Citeline
Open in Who Shared Issue with article?

Orionis Back In Novartis’s Orbit With New Molecular Glue Deal

|
By Manas Mishra 
| Scrip
What: Novartis has signed its second deal with Orionis to discover and design molecular glue drugs for “challenging therapeutic targets”...
Open in Who Shared Issue with article?
See all 5,185 licensed articles (6,160 Total)

Actions

Share this page

Get in touch with Manas

Contact Manas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified